LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

LLY

1,008.2

-0.35%↓

JNJ

229.76

+0.06%↑

ABBV

210.92

+1.82%↑

UNH

397.57

-0.56%↓

AZN

185.49

-0.26%↓

Accueil・Liste d'Actions・Xencor Inc

Xencor Inc

Ouvert

SecteurSoins de santé

11.98 -2.52

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.7

Max

12.45

Chiffres clés
By Trading Economics
Revenu	-214M -129M
Ventes	-24M 4.5M
BPA	-1.71
Marge bénéficiaire	-2,854.65
Employés	260
EBITDA	-81M -75M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+110.02% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-42M 948M
Ouverture précédente	14.5
Clôture précédente	11.98

Sentiment de l'Actualité

By Acuity

50%

162 / 346 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

7.87 / 10.84 Support & Résistance

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 mai 2026, 22:54 UTC

Résultats

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13 mai 2026, 23:17 UTC

Résultats

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mai 2026, 23:16 UTC

Résultats

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mai 2026, 23:15 UTC

Résultats

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mai 2026, 23:14 UTC

Résultats

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mai 2026, 23:02 UTC

Market Talk

Résultats

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mai 2026, 22:59 UTC

Market Talk

Résultats

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mai 2026, 22:24 UTC

Résultats

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mai 2026, 22:23 UTC

Résultats

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mai 2026, 22:23 UTC

Résultats

Xero FY International Revenue Growth 47%>XRO.AU

13 mai 2026, 22:22 UTC

Résultats

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mai 2026, 22:19 UTC

Résultats

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mai 2026, 22:19 UTC

Résultats

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mai 2026, 22:18 UTC

Résultats

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mai 2026, 22:16 UTC

Résultats

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mai 2026, 22:15 UTC

Résultats

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mai 2026, 22:15 UTC

Résultats

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mai 2026, 22:13 UTC

Résultats

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mai 2026, 22:12 UTC

Résultats

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mai 2026, 22:11 UTC

Résultats

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mai 2026, 22:11 UTC

Résultats

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mai 2026, 22:10 UTC

Résultats

Xero Did Not Declare a Dividend>XRO.AU

13 mai 2026, 22:10 UTC

Résultats

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mai 2026, 22:09 UTC

Résultats

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mai 2026, 22:00 UTC

Résultats

Cisco to Shed Jobs for All-In AI Push -- Update

13 mai 2026, 21:11 UTC

Résultats

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

110.02% hausse

Prévisions sur 12 Mois

Moyen 26 USD 110.02%

Haut 43 USD

Bas 13 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

7.87 / 10.84Support & Résistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

162 / 346Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.